Xu J, Wang A, Wangqin R, et al. - Because dual antiplatelet therapy (DAT) with clopidogrel plus aspirin was suggested by American Heart Association/American Stroke Association guidelines for minor stroke (MS) and transient ischemic attack (TIA) patients, researchers sought to identify potential subgroups benefiting from DAT, as well as to compare the effectiveness of clopidogrel–aspirin therapy with that of aspirin therapy in MS/TIA patients stratified by CYP2C19 genotype and risk profiles. CYP2C19 loss-of-function allele (LoFA) carriers have been defined as patients with LoFA of either *2 or *3. There were 1,726 LoFA carriers and 1,068 high-risk patients out of a total of 2,933 MS/TIA patients. No important distinction was discovered in LoFA carriers for stroke recurrence between the group of clopidogrel–aspirin and aspirin alone. Overall, DAT does not benefit LoFA carriers, but there is important advantage to high-risk LoFA carriers. In Chinese MS/TIA patients, the advantage of clopidogrel relies on the genotype and risk profile of CYP2C19.